1 / 15

Disclosures:

gili
Download Presentation

Disclosures:

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Robert W. Harrison, MD; Kyle White, MS; Michael J. Domanski, MD; Sorin J. Brener, MD; Peter K. Smith, MD; Graham S. Hillis, MBChB, PhD; Milo Engoren, MD; John H. Alexander, MD, MHS; Jerrold H. Levy, MD; Bernard R. Chaitman, MD; Michael J. Mack, MD; Michael E. Farkouh, MD, MSc; Kenneth W. Mahaffey, MD Frequency and prognostic importance of troponin and CK-MB elevations following CABG: An analysis from PRIMO I and PRIMO II Duke Clinical Research Institute, Durham, NC (RWH, KW, PKS, JHA, KWM); Mouth Sinai School of Medicine, New York, NY (MJD, MEF); New York Methodist Hospital, Brooklyn, NY (SJB); The George Institute for Global Health, Sydney, Australia (GSH); Mercy St. Vincent Medical Center, Toledo, OH (ME); Emory University, Atlanta, GA (JHL); Saint Louis University Sch. of Med., St. Louis, MO (BRC); Baylor Healthcare, Dallas, TX (MJM)

  2. Disclosures: • R.W. Harrison: None • K. White: None • M.J. Domanski: None • S.J. Brener: None • P.K. Smith: None • G.S. Hillis: None • M. Engoren: None • J.H. Alexander: None • J.H. Levy: None • B.R. Chaitman: None • M.J. Mack: None • M.E. Farkouh: None • K.W. Mahaffey: None

  3. Background • Postoperative myocardial infarction (PMI) is a serious complication of CABG • Incidence 3-20% depending on the definition • Traditionally, PMI defined by postoperative ECG evidence of infarction • More recently, CK-MB and troponin have been incorporated into the definition of PMI • Many contemporary CABG clinical trials have used a combination of CK-MB elevations and Q-waves on ECG to define PMI

  4. Background • Troponin replacing CK-MB in the Universal Definition of Myocardial Infarction1: • Type 5 MI: Postoperative troponin > 10x ULN when associated with ECG changes, or imaging evidence of graft loss or new myocardial injury • Prior studies have demonstrated increased risk of death with elevated CK-MB and troponin2 • Most have evaluated categorical elevations in biomarkers • >5-≤10xULN, >10-≤20xULN, etc. • Little evidence to support the use of specific biomarker thresholds, particularly for troponin. • Thygesen K, et al. Circulation. 2012. 126(16):2020-2035 • Domanski MJ, et al. JAMA. 2011. 305(6) P.585

  5. Objectives • Population of clinical trial participants who underwent systematic assessment of CK-MB and troponin following CABG: • Evaluate the incidence of CK-MB and troponin elevations over a range of thresholds • Assess the association between CK-MB or troponin elevations and 30-day mortality • Assess the independent prognostic importance of ECG evidence of infarction

  6. Methods • PRIMO-I and PRIMO-II: • 7,234 patients • Multicenter randomized clinical trials to assess the efficacy of intravenous pexelizumab in patients undergoing CABG or combined CABG and valve surgery • All patients underwent serial CK-MB, troponin-I (TnI), and ECG measurements over 96 hours • CK-MB: 4, 8, 12, 24, 36, 48, 96 hours • TnI: 24, 48, 96 hours • ECG: enrollment, 48, 96 hours • Biomarkers and ECGs analyzed at a core laboratory

  7. PRIMO-I and PRIMO-II • Enrolled patient with 1 (PRIMO-I) or 2 (PRIMO-II) of the following risk factors: • Urgent CABG • Diabetes mellitus • Female sex • Prior CABG • Prior CVA or neurological event • NYHA Class III-IV CHF • 2 prior MIs, or recent MI (within 4 weeks of CABG) • Preoperative CK-MB and/or TnI abnormalities • Baseline troponin abnormal in 22.2% • Baseline CK-MB abnormal in 8.0% • Overall 30-day mortality: 3.6%

  8. Methods • Analyzed the distributions of peak postoperative CK-MB and TnI elevations. • Unadjusted and adjusted hazard ratios for 30-day mortality determined over a range of thresholds for CK-MB and TnI elevations • Cox Proportional Hazards • Multivariate model incorporates the following predictors: • Biomarker above threshold • Presence/absence of new ECG changes • Covariates: • age, sex, previous MI, renal insufficiency, ejection fraction, diabetes, peripheral vascular disease, hypertension, number of grafts used, cross clamp time, concurrent valve surgery, and use of the internal mammary artery

  9. Results: Baseline data

  10. Results: Biomarker elevation distributions

  11. Results: Biomarker and ECG changes • Proportion of patients affected according to: • Biomarker thresholds • Concomitant ECG changes ECG changes: new Q-waves or LBBB on postoperative ECG

  12. Results: Unadjusted HR for 30-day Mortality Hazard ratios for 30-day mortality were calculated over a range of peak CK-MB and cTnI thresholds defined relative to the ULN.

  13. Results: Adjusted analysis • Adjusted HR for 30-day mortality • Biomarkers and ECG changes as independent predictors of death • Covariates: age, sex, previous MI, renal insufficiency, ejection fraction, diabetes, peripheral vascular disease, hypertension, number of grafts used, cross clamp time, concurrent valve surgery, and use of the internal mammary artery

  14. Limitations • Post-Hoc analysis • Preoperative CK-MB and/or TnI abnormalities • Sensitivity analysis performed • HRs varied <10% after excluding those with baseline abnormal biomarkers • PRIMO-I and PRIMO-II enrolled patients at intermediate to high risk of perioperative events • Standard TnI assay used. Results may not be comparable for high sensitivity assays have lower ULN. • Wide confidence intervals for HRs at low ( 5x ULN for CKMB, 10x ULN for TnI) thresholds • Few patients with few events • Requires cautious interpretation of these point estimates

  15. Conclusions: • Postoperative increases in CK-MB and Troponin-I are common • A higher TnI threshold, vs. CK-MB, is required to affect a similar proportion of patients • CKMB >10xULN (28%) ~ TnI >40xULN (32%) • Concomitant ECG changes occur in a small percentage of patients • CK-MB and TnI elevations were independently predictive of 30-day mortality at all thresholds > 5 x ULN. • Trend: higher thresholds associated with higher HR • New Q-waves or LBBB were weakly associated with 30-day mortality • Prognostic importance wanes at higher biomarker thresholds

More Related